Compare Stocks → The ONE AI Stock to own now. (It’s not Nvidia.) (From Weiss Ratings) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CLPTNASDAQ:DCTHNASDAQ:QIPTNASDAQ:TELA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLPTClearPoint Neuro$6.20-3.1%$6.15$4.05▼$8.99$170.00M0.97122,636 shs78,994 shsDCTHDelcath Systems$7.57+8.8%$5.09$2.25▼$7.99$210.37M0.55315,510 shs335,197 shsQIPTQuipt Home Medical$3.15-7.4%$3.97$3.10▼$6.13$134.10M0.68216,817 shs933,663 shsTELATELA Bio$6.28-1.3%$5.18$4.23▼$11.26$154.87M1184,076 shs93,028 shsThese 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLPTClearPoint Neuro0.00%+5.80%+15.03%-15.30%-29.47%DCTHDelcath Systems0.00%+32.57%+61.24%+72.05%+16.10%QIPTQuipt Home Medical0.00%-21.84%-9.48%-29.37%-47.41%TELATELA Bio0.00%+8.84%+21.94%-13.74%-34.99%The CHIPS Act Motherlode (Ad)If you haven’t heard yet, the CHIPS Act is the US government pouring $280 BILLION into the manufacturing of US semiconductors. A lot of companies will make a fortune from this.Click here to see my #1 investment for 2024.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLPTClearPoint Neuro1.5595 of 5 stars3.52.00.00.02.70.00.6DCTHDelcath Systems3.2507 of 5 stars3.52.00.00.03.64.20.6QIPTQuipt Home Medical1.9566 of 5 stars3.32.00.00.01.30.81.9TELATELA Bio2.3078 of 5 stars3.52.00.00.03.11.70.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLPTClearPoint Neuro3.00Buy$12.0093.55% UpsideDCTHDelcath Systems3.00Buy$20.20166.84% UpsideQIPTQuipt Home Medical2.50Moderate Buy$7.50138.10% UpsideTELATELA Bio3.00Buy$13.00107.01% UpsideCurrent Analyst RatingsLatest DCTH, CLPT, QIPT, and TELA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/17/2024QIPTQuipt Home MedicalStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy$10.50 ➝ $9.505/17/2024QIPTQuipt Home MedicalCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$9.00 ➝ $8.005/17/2024QIPTQuipt Home MedicalRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeMarket Perform ➝ Underperform$10.00 ➝ $2.505/15/2024DCTHDelcath SystemsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $22.005/14/2024DCTHDelcath SystemsStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$25.005/10/2024TELATELA BioPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$12.00 ➝ $10.003/27/2024DCTHDelcath SystemsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$18.00 ➝ $20.003/22/2024TELATELA BioJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$15.003/22/2024TELATELA BioPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$15.00 ➝ $12.003/13/2024CLPTClearPoint NeuroStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $9.00(Data available from 5/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLPTClearPoint Neuro$23.95M7.10N/AN/A$1.26 per share4.92DCTHDelcath Systems$2.07M101.63N/AN/A$0.53 per share14.28QIPTQuipt Home Medical$221.74M0.60$0.82 per share3.83$2.64 per share1.19TELATELA Bio$58.45M2.65N/AN/A$0.58 per share10.83Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLPTClearPoint Neuro-$22.09M-$0.84N/AN/AN/A-78.84%-76.92%-43.94%8/13/2024 (Estimated)DCTHDelcath Systems-$47.68M-$2.65N/AN/AN/A-1,080.72%-290.07%-111.05%8/14/2024 (Estimated)QIPTQuipt Home Medical-$2.78M-$0.10N/A24.23N/A-1.71%-3.89%-1.76%8/12/2024 (Estimated)TELATELA Bio-$46.66M-$1.67N/AN/AN/A-63.82%-155.26%-48.61%8/14/2024 (Estimated)Latest DCTH, CLPT, QIPT, and TELA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2024Q1 2024TELATELA Bio-$0.48-$0.23+$0.25-$0.23$15.90 million$16.60 million 3/26/2024Q4 23DCTHDelcath Systems-$0.67-$0.48+$0.19-$0.48$0.48 million$0.54 million 3/21/2024Q4 2023TELATELA Bio-$0.44-$0.53-$0.09-$0.53$16.65 million$17.00 million3/12/2024Q4 2023CLPTClearPoint Neuro-$0.22-$0.19+$0.03-$0.19$6.40 million$6.81 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLPTClearPoint NeuroN/AN/AN/AN/AN/ADCTHDelcath SystemsN/AN/AN/AN/AN/AQIPTQuipt Home MedicalN/AN/AN/AN/AN/ATELATELA BioN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLPTClearPoint NeuroN/A3.142.61DCTHDelcath SystemsN/A2.522.06QIPTQuipt Home Medical0.671.130.79TELATELA Bio2.834.133.45OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLPTClearPoint Neuro30.08%DCTHDelcath Systems61.12%QIPTQuipt Home Medical42.85%TELATELA Bio94.35%Insider OwnershipCompanyInsider OwnershipCLPTClearPoint Neuro6.11%DCTHDelcath Systems17.94%QIPTQuipt Home Medical4.20%TELATELA Bio6.00%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCLPTClearPoint Neuro10727.42 million25.75 millionOptionableDCTHDelcath Systems7627.79 million22.80 millionOptionableQIPTQuipt Home Medical1,20042.57 million40.78 millionOptionableTELATELA Bio22724.66 million23.18 millionOptionableDCTH, CLPT, QIPT, and TELA HeadlinesRecent News About These CompaniesMay 13, 2024 | marketbeat.comTELA Bio, Inc. (NASDAQ:TELA) Sees Large Increase in Short InterestMay 13, 2024 | finance.yahoo.comTELA Bio, Inc. (NASDAQ:TELA) Q1 2024 Earnings Call TranscriptMay 12, 2024 | investing.comTELA Bio stock target cut, keeps overweight rating on first quarter resultsMay 12, 2024 | msn.comTELA Bio Reports Strong First Quarter Growth, Expands Product PortfolioMay 12, 2024 | msn.comTELA Bio Awards Stock Units to New Employees as Hiring InducementMay 12, 2024 | americanbankingnews.comTELA Bio (NASDAQ:TELA) Rating Reiterated by Piper SandlerMay 11, 2024 | finance.yahoo.comTELA Bio First Quarter 2024 Earnings: US$0.23 loss per share (vs US$0.63 loss in 1Q 2023)May 11, 2024 | finance.yahoo.comTELA Bio Inc (TELA) Reports Q1 2024 Earnings: Revenue Surpasses Estimates Amidst Continued GrowthMay 11, 2024 | markets.businessinsider.comTELA Bio’s Robust Growth and Promising Outlook Merit Bullish StanceMay 10, 2024 | marketbeat.comTELA Bio (NASDAQ:TELA) Posts Quarterly Earnings Results, Beats Estimates By $0.25 EPSMay 10, 2024 | globenewswire.comTELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 10, 2024 | marketbeat.comPiper Sandler Reaffirms Overweight Rating for TELA Bio (NASDAQ:TELA)May 9, 2024 | globenewswire.comTELA Bio Reports First Quarter 2024 Financial ResultsMay 7, 2024 | markets.businessinsider.comLake Street Reaffirms Their Buy Rating on TELA Bio (TELA)May 3, 2024 | msn.comScoPo’s Powerplays: ASX Health stocks rise in big week of quarterly reportsApril 25, 2024 | globenewswire.comTELA Bio to Announce First Quarter 2024 Financial ResultsApril 17, 2024 | msn.comTELA Bio Launches Innovative Hernia Repair Device in the U.S. MarketApril 16, 2024 | msn.comTELA Bio launches OviTex IHR for inguinal hernia repair in USApril 16, 2024 | pharmabiz.comTELA Bio announces US launch OviTex IHR for use in laparoscopic and robotic-assisted inguinal hernia repairApril 15, 2024 | globenewswire.comTELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex® IHR – Addressing the Need for a More Natural Repair in Inguinal Hernia ProceduresApril 11, 2024 | finance.yahoo.comMDXG: Legal AvenuesNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsClearPoint NeuroNASDAQ:CLPTClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.Delcath SystemsNASDAQ:DCTHDelcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.Quipt Home MedicalNASDAQ:QIPTQuipt Home Medical Corp., through its subsidiaries, engages in the provision of durable and home medical equipment and supplies in the United States. The company offers nebulizers, oxygen concentrators, and CPAP and BiPAP units; traditional and non-traditional durable medical respiratory equipment and services; non-invasive ventilation equipment, supplies, and services; and engages in the rental of medical equipment. It offers management of various chronic disease states focusing on patients with heart and pulmonary disease, sleep apnea, reduced mobility, and other chronic health conditions. The company was formerly known as Protech Home Medical Corp. and changed its name to Quipt Home Medical Corp. in May 2021. Quipt Home Medical Corp. is headquartered in Wilder, Kentucky.TELA BioNASDAQ:TELATELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.